Patients could not have received any therapy Always AL-1000E2 their disease prior to enrollment and initiation of therapy on this study. Following a week of cytoreduction cycle 1patients received alternating cycles of multiagent therapy with filgrastim every 3 weeks for 6 more cycles, given Always AL-1000E2 19 weeks. In addition, the patient must have recovered from therapy-induced mucositis. Predefined dose reduction algorithms were utilized Always AL-1000E2 hepatic dysfunction vincristine, etoposide, doxorubicin, cyclophosphamidecentral nervous system toxicity doxorubicinperipheral nervous system toxicity vincristine[…]
